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enthusiasm for the stentless porcine valve was not supported by the
available data.
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REPLY
In Dr. Bloomfield’s letter discussing the Viewpoint (1) and
Commentary (2) recently published in the Journal, Dr. Bloomfield
notes that, in long-term follow-up of the Edinburgh Heart Valve
Trial (3), 1) mortality at 20 years did not differ between mechanical
and tissue prostheses; 2) owing to differences in rates of re-
operation, freedom from all valve-related complications was supe-
rior after mechanical mitral (but not aortic) valve replacement; and
3) over time, an increasing use of anticoagulant therapy was seen
after tissue valve replacement. Dr. Bloomfield concludes that
long-term follow-up of patients in randomized trials is the only
means by which differences between prostheses can be elucidated.
Equivalence of mortality at 20 years supports that, using this
end point, existing data (including those from the Edinburgh
Heart Valve Trial) do not favor one prosthesis type over another.
Freedom from all valve-related complications favors neither pros-
thesis type following aortic valve replacement, which comprises a
preponderance of valve replacement surgeries in the United States;
for both mitral and aortic valves, higher rates of re-operation after
tissue compared with mechanical valve replacement exemplifies an
inherent difference between prostheses. However, re-operation
may be an end point more universally feared by cardiologists than
by patients. Operative mortality for elective “re-do” valve replace-
ment is not substantially different from that for initial surgery.
Whereas some patients may wish to avoid re-operation at all costs,
others are clearly willing, if given the option, to face the near-
certainty of additional surgery in order to avoid daily anticoagula-
tion. This argument is not obviated by an early experience showing
increasing requirement over time for anticoagulation due to atrial
fibrillation. Atrial fibrillation carries a lower thromboembolic risk
(and therefore requires less aggressive anticoagulation) compared
with mechanical mitral valve replacement. Moreover, earlier inter-
vention as well as newer medical therapies and surgical and
percutaneous procedures presently available for the treatment of
atrial arrhythmias can be expected to lower the need for additional
long-term anticoagulation compared with the cohort studied from
the 1970s.
The tenet of the previously published Viewpoint (1) is not that
long-term data are not desirable, but that for prosthetic valve
choices that are made today, pertinent long-term, randomized data
do not (and will never) exist. Although Dr. Bloomfield and his
co-investigators (3) are to be commended for their study, the data
as they relate to current decisions in prosthetic valve surgery are
moot. In 2004, neither the Bjork-Shiley nor the original Hancock
valve is available for implantation. Future randomized studies are
unrealistic, and even if performed, valve technology would again
have evolved by the time long-term data became available. Rather
than attempting to extrapolate to current practice “tissue versus
mechanical” data from valves that are obsolete and in some cases
known to be poorly representative of currently available prostheses,
this author asks the clinician to understand the limitations of these
data, and to recognize that the gradual and continuing advances
made in heart valve prostheses make a demand for only long-term,
randomized data unrealistic and therefore unwise.
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Increased Randomness of
Heart Rate Could Explain
Increased Heart Rate Variability
Preceding Onset of Atrial Fibrillation
The recent study in JACC by Amar et al. (1) describes significant
increases in heart rate variability (HRV) in the period preceding
the onset of atrial fibrillation (AF) in postoperative patients. This
increase in HRV is interpreted by the investigators as reflecting
increased parasympathetic and sympathetic activity. Whereas this
is a possible explanation, another equally plausible explanation
requires testing. We propose that the increase in HRV is due to an
increase in the randomness of the heart-period signal, associated
with a marked increase in sympathetic activation. This would be
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consistent with a study in normals in which increasing doses of
norepinephrine produced increased randomness of heart rate
patterns (2). This hypothesis could easily be tested using multiple
methods. One would be to plot the HRV power spectrum. If there
were, indeed, an increase in vagal modulation of heart rate, there
would be a clear increase in the size of a clearly seen peak in the
high-frequency band. If an increase in randomness occurred, any
increase in high-frequency power would be associated with an
increasingly broad and abnormal-looking peak.
Alternatively, the Poincare´ plot (a plot of each normal-to-
normal interval vs. the next) could be generated. Increased ran-
domness would be associated with an increasingly complex-
looking plot (3). Finally, nonlinear HRV indices could be
calculated. The calculation of the short-term fractal scaling expo-
nent (4) would normally require about 1,000 beat-segments of
data. The ratio of the axes of an ellipse fitted to the Poincare´ plot
(SD12) could be calculated for the same 5-min segments that were
used for HRV. Increasing values of SD12, or decreasing values of
the short-term scaling exponent, would be consistent with increas-
ing randomness, rather than increased levels of autonomic modu-
lation of the heart. Indeed, this technique has previously been
applied to ventricular tachycardias, and increased SD12 was found
to precede arrhythmic events (5).
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REPLY
We thank Dr. Stein for her interest and comments. Although we
would like to study nonlinear methods in our patients, this task was
prohibitive in the time frame required for this response. We
appreciate the suggestions and will explore our data using these
methods in the future.
Dr. Stein suggests that postoperative patients behave similarly
to healthy volunteers in whom increased randomness of the
heart-period signal was attributed to increasing doses of norepi-
nephrine (1) and that the increases in both time- and frequency-
domain parameters of heart rate variability (HRV) observed in our
study do not represent vagal resurgence (2). We disagree with this
hypothesis for several reasons.
First, in a study of patients undergoing major thoracic or
abdominal surgery, we showed persistent downregulation and
desensitization of the lymphocyte beta-adrenergic receptor/
adenylyl cyclase system, which correlated with decrements in time-
and frequency-domain indices of HRV throughout the first week
after surgery (3). These changes occurred in the absence of change
in perioperative epinephrine or norepinephrine levels.
Second, to suggest that our atrial fibrillation (AF) patients (n 
48) had a significantly different perioperative neurohumoral re-
sponse than did that of controls (n  48) matched for age, gender,
and identical operation, appears unlikely. Finally, the HRV re-
sponse seen in our control group was very similar to that seen in
other patients undergoing major thoracic surgery, supporting the
presence of parasympathetic withdrawal and not resurgence (4).
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Measurement of Circulating Vascular
Endothelial Growth Factor in Obese Subjects
I read with interest the report by Rehman et al. (1) evaluating the
circulating levels of hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF) in obese subjects. Although the
investigators should be congratulated by their results on the study
of HGF, I would like to underline some methodological concerns
regarding the measurement of VEGF levels.
Serum VEGF is not a suitable indicator of circulating extracel-
lular VEGF levels at the time of sampling; VEGF is stored in the
-granules of platelets and is released during blood clotting. As a
consequence, VEGF level in the serum is several-fold higher than
that in matched plasma samples (2,3). In plasma, platelet degran-
ulation is minimized by adding anticoagulants to the blood
samples; in particular, CTAD (citrate, theophylline, adenosine,
dipyridamole) plasma is recommended for the measurement of
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